Actinium Pharmaceuticals (NYSE:ATNM) Coverage Initiated by Analysts at started coverage on shares of Actinium Pharmaceuticals (NYSE:ATNMGet Rating) in a research note published on Thursday. The brokerage issued a sell rating on the stock.

Actinium Pharmaceuticals Price Performance

Shares of NYSE:ATNM opened at $8.68 on Thursday. Actinium Pharmaceuticals has a 52-week low of $4.67 and a 52-week high of $15.12. The company has a market capitalization of $223.34 million, a price-to-earnings ratio of -5.56 and a beta of 0.38.

Actinium Pharmaceuticals Company Profile

(Get Rating)

Actinium Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. It also develops and markets medicines for relapsed or refractory cancer patients. The company was founded in 2000 and is headquartered in New York, NY.

See Also

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with's FREE daily email newsletter.